Results 11 to 20 of about 14,047 (222)

Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. [PDF]

, 2014
Barretts esophagus (BE) involves a metaplastic replacement of native esophageal squamous epithelium (Sq) by columnar-intestinalized mucosa, and it is the main risk factor for Barrett-related adenocarcinoma (BAc).
Baffa, R, Bornschein, J, Braconi, C, Croce, CM, D'Angelo, E, Dall'Olmo, L, Fassan, M, Galasso, M, Gasparini, P, Nuovo, GJ, Pizzi, M, Realdon, S, Rugge, M, Souza, RF, Valeri, N, Vicentini, C, Volinia, S, Zaninotto, G   +17 more
core   +4 more sources

DUOX2 Expression Is Increased in Barrett Esophagus and Cancerous Tissues of Stomach and Colon

Gastroenterology Research and Practice, 2016
Aim. To detect the expression of dual oxidase (DUOX) 2 in Barrett esophagus, gastric cancer, and colorectal cancer (CRC). Materials and Methods. The endoscopic biopsies were collected from patients with Barrett esophagus, while the curative resection ...
Ran Qi, Yunfeng Zhou, Xiaozhen Li, Hong Guo, Lei Gao, Lijuan Wu, Yufeng Wang, Qiang Gao   +7 more
doaj   +1 more source

Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?

The Turkish Journal of Gastroenterology, 2017
Besides reducing the reflux symptoms, the benefit of proton pump inhibitors (PPI) in the treatment of Barrett's esophagus (BE) is not exactly known.
Hakan Akın, Yücel Aydın
doaj   +1 more source

Recurrence of intestinal metaplasia and early neoplasia after endoscopic eradication therapy for Barrett’s esophagus: A systematic review and meta-analysis [PDF]

, 2017
Background Conflicting data exist with regard to recurrence rates of intestinal metaplasia (IM) and dysplasia after achieving complete eradication of intestinal metaplasia (CE-IM) in Barrett’s esophagus (BE) patients.
Cinnor, Birtukan, Das, Ananya, Early, Dayna S, Edmundowicz, Steven A, Fujii-Lau, Larissa L, Gaddam, Srinivas, Komanduri, Srinadh, Kushnir, Vladimir, Mullady, Daniel, Muthusamy, V. Raman, Shaheen, Nicholas, Simon, Violette C, Wani, Sachin, Wilson, Robert   +13 more
core   +2 more sources

Origin of adenocarcinoma in Barrett's esophagus: P53 and Ki67 expression and histopathologic background Origem do adenocarcinoma no esôfago de Barrett: bases histopathológicas e expressão dos genes p53 e Ki67

Clinics, 2005
Barrett's esophagus is the substitution of squamous epithelium of the distal esophagus by columnar epithelium. Intestinal metaplasia in Barrett's esophagus is considered to be the main risk factor for the development of adenocarcinoma.
Sergio Szachnowicz, Ivan Cecconello, Kiyoshi Iriya, Allan Garms Marson, Flávio Roberto Takeda, Joaquim José Gama-Rodrigues   +5 more
doaj   +1 more source

Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. [PDF]

PLoS Genetics, 2011
Although a combination of genomic and epigenetic alterations are implicated in the multistep transformation of normal squamous esophageal epithelium to Barrett esophagus, dysplasia, and adenocarcinoma, the combinatorial effect of these changes is unknown.
Hector Alvarez, Joanna Opalinska, Li Zhou, Davendra Sohal, Melissa J Fazzari, Yiting Yu, Christina Montagna, Elizabeth A Montgomery, Marcia Canto, Kerry B Dunbar, Jean Wang, Juan Carlos Roa, Yongkai Mo, Tushar Bhagat, K H Ramesh, Linda Cannizzaro, J Mollenhauer, Reid F Thompson, Masako Suzuki, Stephen J Meltzer, Ari Melnick, John M Greally, Anirban Maitra, Amit Verma   +23 more
doaj   +1 more source

The esophagogastric junctional adenocarcinoma an increasing disease [PDF]

, 2017
Identifying and defining the esophagogastric junctional adenocarcinoma (EGJA) as an independent disease apart from gastric cancer (GC) and esophagus cancer (EG) it has always been a difficult issue entailing doubts about the appropriate therapeutic ...
Andreetti, Claudio, Ibrahim, Mohsen, Menna, Cecilia, Pastina, Monica   +3 more
core   +1 more source

Prevalence of Barrett's esophagus in individuals without typical symptoms of gastroesophageal reflux disease Prevalência do esôfago de Barrett em indivíduos sem sintomas típicos da doença por refluxo gastroesofágico

Arquivos de Gastroenterologia, 2008
BACKGROUND: Barrett’s esophagus, the major risk factor for esophageal adenocarcinoma, is detected in approximately 10%-14% of individuals submitted to upper endoscopy for the assessment of gastroesophageal reflux disease related symptoms.
Mauro Carneiro de Freitas, Luciana Dias Moretzsohn, Luiz G. V. Coelho   +2 more
doaj   +1 more source

Endoscopic therapy for Barrett′s esophagus

Journal of Digestive Endoscopy, 2012
Barrett’s esophagus (BE) is the precursor lesion to esophageal adenocarcinoma. This cancer has undergone a rapid increase in incidence in Western societies in the last 30 years.
Nicholas J. Shaheen
doaj   +1 more source

Barrett Esophagus [PDF]

Mayo Clinic Proceedings, 2019
Barrett esophagus is a metaplastic change in the lining of the distal esophageal epithelium, characterized by replacement of the normal squamous epithelium by specialized intestinal metaplasia. The presence of Barrett esophagus increases the risk of esophageal adenocarcinoma several-fold.
Prasad G. Iyer, Vivek Kaul
openaire   +2 more sources